BH 3120
Alternative Names: BH-3120Latest Information Update: 04 Jul 2025
At a glance
- Originator Hanmi Pharmaceutical
- Developer Hanmi Pharmaceutical; Merck Sharp & Dohme
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 12 Jun 2025 3898567 - updated - kdm, pd, HE
- 25 Apr 2025 Adverse events data from preclinical studies in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025) .
- 25 Apr 2025 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025) .